Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Brand collaborations remain a popular tactic for challenger brands to reach new audiences. Bubble Skincare and Touchland will share what goes into a mutually beneficial partnership, offering a look at ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

It spent $679 million on marketing in 2024, which was 46% of its revenue. However, given how fast revenue is growing and its positive free cash flow, Hims & Hers seems to be getting a good return ...

Hims & Hers ramped up its marketing spend in the quarter, but was able to show marketing leverage, with marketing expense as a percentage of revenue falling year over year. Marketing spending ...